Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery

Julie Brown, Anne Lethaby, Heather Maxwell, Andrew Wawrzyniak, Martin H. Prins

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background: Peripheral arterial disease (PAD) may cause occlusions (blockages) in the main arteries of lower limbs. One treatment option is bypass surgery using autologous (the patient's own tissue) vein graft or artificial graft. A number of factors influence occlusion rates, including the material used. To prevent graft occlusion patients are usually treated with antiplatelet, antithrombotic drugs, or a combination of both. Objectives: To evaluate whether antiplatelet treatment in patients with symptomatic PAD undergoing infrainguinal bypass surgery improves graft patency, limb salvage and survival. Search strategy: The authors searched the Cochrane Peripheral Vascular Diseases Group Specialised Register (January 2008) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, Issue 4). Additional trials were sought through reference lists of papers and proceedings from the vascular surgical society meetings. Selection criteria: For this update the methodological quality of each original trial was assessed independently by review authors (JB, HM, AW) with emphasis on concealment of allocation. Data collection and analysis: Details of the selected studies were extracted independently by JB and HM for the update. The treatment and control groups were compared for important prognostic factors and differences described. If any data were unavailable, further information was sought from authors. Data were synthesised by comparing group results. Unit of analysis issues were addressed by subgroup analysis. Main results: The administration of a variety of platelet inhibitors resulted in improved venous and artificial graft patency when compared to no treatment. However, analysing patients for graft-type indicated that those patients receiving a prosthetic graft were more likely to benefit from administration of platelet inhibitors than patients treated with venous grafts. Authors' conclusions: Antiplatelet therapy with aspirin had a slight beneficial effect on the patency of peripheral bypass grafts but seemed to have an inferior effect on venous graft patency compared with artificial grafts. The effect of aspirin on cardiovascular outcomes and survival was small and not statistically significant. This might be due to the fact that the majority of patients receiving a peripheral graft have an advanced stage of PAD with critical ischaemia. They are usually seriously ill as a result of cardiovascular disease and have high mortality rates, of 20% per year. Additionally, the number of patients included in this analysis might be too small to reach a statistically significant effect for mortality and cardiovascular morbidity.

Original languageEnglish
Article numberCD000535
JournalCochrane Database of Systematic Reviews
Issue number4
DOIs
StatePublished - Nov 5 2008
Externally publishedYes

Fingerprint

Platelet Aggregation Inhibitors
Thrombosis
Transplants
Peripheral Arterial Disease
Aspirin
Therapeutics
Limb Salvage
Survival
Peripheral Vascular Diseases
Mortality
Patient Selection
Libraries
Blood Vessels
Lower Extremity
Veins
Cardiovascular Diseases
Ischemia
Arteries

Keywords

  • Arteriosclerosis [*surgery]
  • Graft occlusion, vascular [*prevention & control]
  • Intermittent claudication [surgery]
  • Peripheral vascular diseases [*surgery]
  • Platelet aggregation inhibitors [*therapeutic use]

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. / Brown, Julie; Lethaby, Anne; Maxwell, Heather; Wawrzyniak, Andrew; Prins, Martin H.

In: Cochrane Database of Systematic Reviews, No. 4, CD000535, 05.11.2008.

Research output: Contribution to journalArticle

@article{babf004e9f6b4731ae68e7c37804fa7c,
title = "Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery",
abstract = "Background: Peripheral arterial disease (PAD) may cause occlusions (blockages) in the main arteries of lower limbs. One treatment option is bypass surgery using autologous (the patient's own tissue) vein graft or artificial graft. A number of factors influence occlusion rates, including the material used. To prevent graft occlusion patients are usually treated with antiplatelet, antithrombotic drugs, or a combination of both. Objectives: To evaluate whether antiplatelet treatment in patients with symptomatic PAD undergoing infrainguinal bypass surgery improves graft patency, limb salvage and survival. Search strategy: The authors searched the Cochrane Peripheral Vascular Diseases Group Specialised Register (January 2008) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, Issue 4). Additional trials were sought through reference lists of papers and proceedings from the vascular surgical society meetings. Selection criteria: For this update the methodological quality of each original trial was assessed independently by review authors (JB, HM, AW) with emphasis on concealment of allocation. Data collection and analysis: Details of the selected studies were extracted independently by JB and HM for the update. The treatment and control groups were compared for important prognostic factors and differences described. If any data were unavailable, further information was sought from authors. Data were synthesised by comparing group results. Unit of analysis issues were addressed by subgroup analysis. Main results: The administration of a variety of platelet inhibitors resulted in improved venous and artificial graft patency when compared to no treatment. However, analysing patients for graft-type indicated that those patients receiving a prosthetic graft were more likely to benefit from administration of platelet inhibitors than patients treated with venous grafts. Authors' conclusions: Antiplatelet therapy with aspirin had a slight beneficial effect on the patency of peripheral bypass grafts but seemed to have an inferior effect on venous graft patency compared with artificial grafts. The effect of aspirin on cardiovascular outcomes and survival was small and not statistically significant. This might be due to the fact that the majority of patients receiving a peripheral graft have an advanced stage of PAD with critical ischaemia. They are usually seriously ill as a result of cardiovascular disease and have high mortality rates, of 20{\%} per year. Additionally, the number of patients included in this analysis might be too small to reach a statistically significant effect for mortality and cardiovascular morbidity.",
keywords = "Arteriosclerosis [*surgery], Graft occlusion, vascular [*prevention & control], Intermittent claudication [surgery], Peripheral vascular diseases [*surgery], Platelet aggregation inhibitors [*therapeutic use]",
author = "Julie Brown and Anne Lethaby and Heather Maxwell and Andrew Wawrzyniak and Prins, {Martin H.}",
year = "2008",
month = "11",
day = "5",
doi = "10.1002/14651858.CD000535.pub2",
language = "English",
journal = "The Cochrane database of systematic reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery

AU - Brown, Julie

AU - Lethaby, Anne

AU - Maxwell, Heather

AU - Wawrzyniak, Andrew

AU - Prins, Martin H.

PY - 2008/11/5

Y1 - 2008/11/5

N2 - Background: Peripheral arterial disease (PAD) may cause occlusions (blockages) in the main arteries of lower limbs. One treatment option is bypass surgery using autologous (the patient's own tissue) vein graft or artificial graft. A number of factors influence occlusion rates, including the material used. To prevent graft occlusion patients are usually treated with antiplatelet, antithrombotic drugs, or a combination of both. Objectives: To evaluate whether antiplatelet treatment in patients with symptomatic PAD undergoing infrainguinal bypass surgery improves graft patency, limb salvage and survival. Search strategy: The authors searched the Cochrane Peripheral Vascular Diseases Group Specialised Register (January 2008) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, Issue 4). Additional trials were sought through reference lists of papers and proceedings from the vascular surgical society meetings. Selection criteria: For this update the methodological quality of each original trial was assessed independently by review authors (JB, HM, AW) with emphasis on concealment of allocation. Data collection and analysis: Details of the selected studies were extracted independently by JB and HM for the update. The treatment and control groups were compared for important prognostic factors and differences described. If any data were unavailable, further information was sought from authors. Data were synthesised by comparing group results. Unit of analysis issues were addressed by subgroup analysis. Main results: The administration of a variety of platelet inhibitors resulted in improved venous and artificial graft patency when compared to no treatment. However, analysing patients for graft-type indicated that those patients receiving a prosthetic graft were more likely to benefit from administration of platelet inhibitors than patients treated with venous grafts. Authors' conclusions: Antiplatelet therapy with aspirin had a slight beneficial effect on the patency of peripheral bypass grafts but seemed to have an inferior effect on venous graft patency compared with artificial grafts. The effect of aspirin on cardiovascular outcomes and survival was small and not statistically significant. This might be due to the fact that the majority of patients receiving a peripheral graft have an advanced stage of PAD with critical ischaemia. They are usually seriously ill as a result of cardiovascular disease and have high mortality rates, of 20% per year. Additionally, the number of patients included in this analysis might be too small to reach a statistically significant effect for mortality and cardiovascular morbidity.

AB - Background: Peripheral arterial disease (PAD) may cause occlusions (blockages) in the main arteries of lower limbs. One treatment option is bypass surgery using autologous (the patient's own tissue) vein graft or artificial graft. A number of factors influence occlusion rates, including the material used. To prevent graft occlusion patients are usually treated with antiplatelet, antithrombotic drugs, or a combination of both. Objectives: To evaluate whether antiplatelet treatment in patients with symptomatic PAD undergoing infrainguinal bypass surgery improves graft patency, limb salvage and survival. Search strategy: The authors searched the Cochrane Peripheral Vascular Diseases Group Specialised Register (January 2008) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, Issue 4). Additional trials were sought through reference lists of papers and proceedings from the vascular surgical society meetings. Selection criteria: For this update the methodological quality of each original trial was assessed independently by review authors (JB, HM, AW) with emphasis on concealment of allocation. Data collection and analysis: Details of the selected studies were extracted independently by JB and HM for the update. The treatment and control groups were compared for important prognostic factors and differences described. If any data were unavailable, further information was sought from authors. Data were synthesised by comparing group results. Unit of analysis issues were addressed by subgroup analysis. Main results: The administration of a variety of platelet inhibitors resulted in improved venous and artificial graft patency when compared to no treatment. However, analysing patients for graft-type indicated that those patients receiving a prosthetic graft were more likely to benefit from administration of platelet inhibitors than patients treated with venous grafts. Authors' conclusions: Antiplatelet therapy with aspirin had a slight beneficial effect on the patency of peripheral bypass grafts but seemed to have an inferior effect on venous graft patency compared with artificial grafts. The effect of aspirin on cardiovascular outcomes and survival was small and not statistically significant. This might be due to the fact that the majority of patients receiving a peripheral graft have an advanced stage of PAD with critical ischaemia. They are usually seriously ill as a result of cardiovascular disease and have high mortality rates, of 20% per year. Additionally, the number of patients included in this analysis might be too small to reach a statistically significant effect for mortality and cardiovascular morbidity.

KW - Arteriosclerosis [surgery]

KW - Graft occlusion, vascular [prevention & control]

KW - Intermittent claudication [surgery]

KW - Peripheral vascular diseases [surgery]

KW - Platelet aggregation inhibitors [therapeutic use]

UR - http://www.scopus.com/inward/record.url?scp=55049130542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55049130542&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD000535.pub2

DO - 10.1002/14651858.CD000535.pub2

M3 - Article

JO - The Cochrane database of systematic reviews

JF - The Cochrane database of systematic reviews

SN - 1361-6137

IS - 4

M1 - CD000535

ER -